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Abstract
Nowadays, the complementary diagnostics based on the suspicious thyroid lesion specific mutational state analysis is indispens-
able in the clinical practice. We aimed to test and validate our novel 568-mutational hotspot panel (23 cancer-related genes) on
papillary thyroid cancers (PTCs) and their tumor-free pairs to find the most powerful mutation pattern related to PTC. The
sequencing method was carried on with Ion Torrent PGM on 67 thyroid tissue samples. The most commonly detected mutation
was the BRAF c.1799 T >A in all non-classical PTC cases. We utilized a multivariate statistical method (CVA) to determine a
discrimination score based on mutational data array and to assess malignancy risk. Based on variants, the BRAF gene has by far
the highest indicative power, followed by TSHR and APC. We highlighted novel aspects of the mutational profile and genetic
markers of PTC. CVA has correctly assigned most of the samples based on the mutation frequencies and different variables of the
selected genes, with high analytical probabilities. The final goal is to set up a new comprehensive rule-in and rule-out test to
support the clinical decision making mainly in inconclusive fine-needle aspiration biopsy cases.
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Abbreviations
A U S /
FLUS
Atypia of undetermined significance/follicular le-
sion of undetermined significance
COSMIC Catalogue Of Somatic Mutations In Cancer
CVA Canonical variates analysis
DNA Deoxyribonucleic acid
FNAB Fine needle aspiration biopsy
FNAC Fine needle aspiration cytology
FN/SFN Follicular neoplasm/suspicious for follicular
neoplasm
IGV Integrative genomics viewer
INDEL Insertion-deletion polymorphisms
PBS Phosphate-buffered saline
PTC Papillary thyroid cancer
SM Suspicious for malignancy
SNV Single nucleotide variant
NGS next generation sequencing
Introduction
Thyroid cancer found in nodules of the gland is the most
common endocrine malignancy (approximately 2.0–3.0% of
all new cancers diagnosed each year in the USA) and its inci-
dence is continuously growing worldwide during the recent
decades [1]. The vast majority (60–80%) of thyroid cancers
are well-differentiated papillary thyroid carcinomas (PTC) [2].
PTC tissues often dispose somatic mutations in the MAPK
pathway elements, namely BRAF, HRAS, KRAS and NRAS,
as well as in one of the most important tumor suppressor TP53
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gene. BRAF c.1799 T > A (V600E) is considered the most
prevalent genetic alteration in PTC, and it has also been asso-
ciated with more aggressive tumor behavior, such as
extrathyroidal extension, lymph node involvement, resistance
to radioactive iodine and tumor recurrence. Beside these com-
mon oncogenic mutations, rearrangements of PAX8/PPARG
and RET/PTC genes are also notable in PTC variants [3].
Approximately 70% of differentiated thyroid tumors demon-
strate one abnormalities of the four driver genes or either one
of two chromosomal rearrangements [4]. In addition, newly
identified genomic alterations have been implicated in the
pathogenesis of differentiated thyroid cancers. These are also
involved e.g. in AKT regulation (PIK3CA) and tumor suppres-
sion (PTEN). Simultaneous testing of the well-known driver
genes and the novel ones combined with the histological find-
ings facilitate more accurate clinical results. Furthermore, this
approach might have potential usage in the complementary
diagnostics of suspicious thyroid lesions.
The prevalence of palpable nodules in the thyroid gland is
4–7% [5], however, non-palpable and non-visible nodules are
more frequent, altogether 20–50% of the population are af-
fected depending on the method used to detect [6]. Majority of
malignant lesions can be identified in cold nodules, i.e. nod-
ules not taking up radioiodine. Fine needle aspiration cytology
(FNAC) is the gold standard for the examination of different
nodules. However, 10–40% of the biopsy cases will provide
indeterminate diagnostic results: i, Bethesda III, atypia of un-
determined significance/follicular lesion of undetermined sig-
nificance (AUS/FLUS); ii, Bethesda IV, follicular neoplasm/
suspicious for follicular neoplasm (FN/SFN); and iii,
Bethesda V, suspicious for malignancy (SM) result [7, 8].
Recent studies [9, 10] showed that precancerous cytology
completed with genetic testing may give a more precise diag-
nosis. Moreover, some somatic aberrations found in benign
nodules could change the clinical decision making [8].
Tissue specific somatic mutation pattern analyses need sen-
sitive, high-throughput, robust and cost-effective technology.
Next generation sequencing (NGS) is capable of analyzing a
huge number of genetic hotspots with as low as 5% allele
frequency in one step. Recently, several multi-gene panels
have been developed for thyroid tissue examination [11–13].
Our group established a novel generation of targeted sequenc-
ing panel for multiple mutational profiling in genes demon-
strating significant role in thyroid carcinogenesis. This extend-
ed panel contains genetic variations that may lead to activation
of the MAPK/MET/PI3K-AKT pathways or protooncogenes,
as well as compromise the tumor suppressor function, based
on a number of recent discoveries, including those reported by
the National Cancer Genome Atlas Research Network in thy-
roid cancer cases [4]. In this work, we aimed to retrospectively
test and validate our 568-mutational hotspot panel on PTC
samples and their tumor-free pairs to find the most powerful
mutation pattern related to papillary cancer. The final goal is to
set up a new comprehensive rule-in and rule-out test to sup-
port the clinical decision making mainly in inconclusive
FNAB cases, based on these preliminary results.
Materials and Methods
Biological Samples and Genomic DNA Isolation
In our present study, we analyzed genomic DNA from freshly
frozen intraoperative samples of primary papillary thyroid car-
cinomas with matched tumor-free tissues. Samples were col-
lected from patients undergo thyroidectomy at 1st Department
of Surgery, Semmelweis University, between 2010 and 2016.
All surgically removed thyroid tissue samples underwent de-
tailed histological examination, and papillary carcinoma was
identified in all cases. We excluded such samples when thy-
roid cancer was considered as metastatic secondary tumor. We
examined 67 thyroid tissue samples, 39 with PTC and 28
tumor-free thyroid tissues. There were 27 sample pairs, i.e.
both PTC and tumor-free thyroid tissues originated from the
same patient, and 12 PTCs and 1 tumor-free tissue sample
from different patients. Thus, samples were obtained from
40 patients. The study was approved by the National
Committee for Research Ethics, and all patients gave written
informed consent.
Intraoperative thyroid tissues were stored at −80 °C until
processed. The samples were homogenized in phosphate-
buffered saline (PBS) by Fisher Scientific Power Gen tissue
grinder (Fisher Scientific GmbH, Germany). From each sam-
ple (tumor-free and cancerous), genomic DNAwas separated
by Roche High Pure PCR template Preparation Kit (Roche
Indianapolis, IN, USA) according to the manufacturer’s pro-
tocol. The concentration of the isolated gDNAwas determined
using the Qubit dsDNA HS Assay Kit (Thermo Fisher,
Waltham, MA, USA) and the quality was assessed using
NanoDrop spectrophotometer (NanoDrop Technologies,
Montchanin, DE, USA) at 260/ 280 nm. Our samples were
characterized by LightCycler melting curve analysis for
BRAF codon 600, KRAS codons 12 and 13, NRAS codon
61 and HRAS codon 61 [2].
Ion Torrent Sequencing
A custom-made AmpliSeq hotspot panel was designed, using
the AmpliSeq Designer software (Thermo Fisher, Waltham,
MA, USA), targeting the relevant parts of coding sequences of
23 cancer-relate genes (AKT1, APC, AXIN1, BRAF, C16orf3,
CTNNB1, DICER1, EIF1AX, GNAS, HRAS, IDH1, KRAS,
LPAR4, MET, NRAS, PIK3CA, PTEN, RET, SMAD4, TERT,
TP53, TSHR, VHL) which contains 568 known mutational
hotspot areas with COSMIC IDs. The design process resulted
in a total of 101 amplicons. To gain a higher coverage of the
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regions of interest, we designed the primers to flank some
parts of the nearby introns, as well. Amplicon library was
prepared using the Ion AmpliSeq Library Kit 2.0 (Thermo
Fisher); briefly, multiplex primer pools were added to 10 ng
of genomic DNA and amplified with the following PCR cy-
cles: at 99 °C for 2 min, at 99 °C for 15 s, and at 60 °C for
4 min (21 cycles), and holding on at 10 °C. Primers were
partially digested using a FuPa reagent, and then sequencing
adapters were ligated to the amplicons. The library was puri-
fied in multiple times using the Agencourt AMPure XP
Reagent (Beckmann Coulter, CA, USA). The concentration
of the final library was determined by fluorescent measure-
ment on Qubit 2.0 instrument (Thermo Fisher). Template
preparation was performed with Ion PGM™ Hi-Q View
OT2 kit (Thermo Fisher) on semiautomated Ion OneTouch 2
instrument using an emPCRmethod. After breaking the emul-
sion, the nontemplated beads were removed from the solution
during the semiautomated enrichment process on Ion
OneTouch ES (Thermo Fisher) instrument. After adding the
sequencing primer and polymerase, the fully prepared Ion
Sphere Particle (ISP) beads were loaded into an Ion 314v2
BC sequencing chip. Four samples loaded in one chip. The
sequencing runs were performed using the Ion PGM™ Hi-
Q™ View Sequencing kit (Thermo Fisher) with 500 flows.
Data Analysis
Data from the Ion Torrent runs were analyzed using the
platform-specific pipeline software Torrent Suite v5.0.4 for
base calling, trim adapter and primer sequences, filtering out
polyclonal and poor-quality reads, then de-multiplex the reads
according to the barcode sequences. Briefly, TMAP (https://
github.com/iontorrent/TMAP) algorithmwas used to align the
reads to the hg19 human reference genome, and then, the
variant caller plug-in was selected to run to search for somatic
variants in the targeted regions. Ion Reporter 5.0 was used for
variant annotation. Variants with more than 1% population
frequency were removed from the datasets. Alterations which
are covered at least with 5 reads and presents in both strands
were selected for further analysis. Integrative genomics view-
er (IGV) was used for visualization of the mapped reads. We
assessed the pathogenicity of the variants with SIFT and
PolyPhen-2 algorithms.
Canonical Variates Analysis
Data were evaluated at two levels, those of the variants and the
genes. In the first case, we compiled a loci by patients matrix
with 59 rows (identified variants on 18 genes) and 67 columns
(samples) in which 0 indicated no mutation and 1
corresponded to mutation. This matrix was very sparse be-
cause most variants were detected in only one or two samples
which have very low indicator value. We therefore reduced
the data matrix to 26 by 67 by retaining those variants which
occurred at least three times in the data. In the second case, the
genes by patients data matrix of size 18 by 67 was generated
by counting the number of variants detected for each gene in
each patient.
The objective of our study was to select variants and genes
that may be best used to predict the tumorous or benign state
of the thyroid. Both data matrices were used as a training set in
canonical variates analysis (CVA, alias discriminant analysis).
Since the data obviously do not meet the statistical require-
ments for hypothesis testing, our goal was mainly exploratory.
In other words, CVA is robust enough to give rough estimates
of classification probabilities, while the use of canonical func-
tions to classify unknowns was not warranted. Since the num-
ber of groups was 2, the analysis resulted in a single canonical
variate for both sets of data. Correlations between the canon-
ical variates and the original variables (26 variants or 18
genes) were calculated as a measure of their discriminatory
– or tumor-indicative - power in separating the groups. For the
purpose of estimating tumor risk, we formally used the sum of
F-values (the ratio of between-group and within-group vari-
ances for each variable) derived from the training set: the
larger this empirical value, the higher the risk. Due to the
aforementioned statistical problems, no probability level
could be associated to this statistic. We used the SYN-TAX
2000 package for computations [14].
Results
Descriptive Statistics
Ninemales and 31 females participated in the study. Themean
age of men was 55.1 years (range: 37–80 years) and in case of
women was 49.5 years (range: 27–80 years). The papillary
thyroid cancer samples were classified into seven histological
subtypes. Twenty-four samples were recognized as classical
PTC and 15 were different PTC variants as follicular (n = 4),
encapsulated (n = 3), oncocytic (n = 4), multifocal type (n = 1)
and microcarcinoma (n = 3). The largest tumor size occurred
in follicular PTC variants (avg. diameter = 18.8 mm).
Tumorous lesions affected both thyroid lobes beside multifo-
cal type of PTC in case of classical and encapsulated variants.
The basic characteristics of the specimens were shown in
Table 1.
Quality Assessment of the Targeted Sequencing Data
The average read number was 143.211 reads per sample. The
average base coverage depth was 642 (121–2.290) (Suppl.
Table 1) and the average 1× target coverage was about
98.2% with a mean raw accuracy over 99%. The uniformity
of coverage was between 54.4 and 93.2%.
103Targeted Mutational Profiling and a Powerful Risk Score as Additional Tools for the Diagnosis of Papillary...
Mutational Profiling of PTC Samples Compared
to Tumor-Free Tissue
Twenty-three relevant thyroid and thyroid cancer-related
genes were tested on 568 known mutational hotspot areas in
our 67 samples. Altogether 61 non-synonymous variants (36
SNVs: 35missense and 1 nonsense; 25 INDELs: 24 insertions
and 1 non-frameshift deletion) detected met the criteria
concerning variant analysis (covered at least with 5 reads
and presents in both strands). From all genetic alterations
found, 31 were previously reported in COSMIC database.
We were able to identify additional 30 novel variants sur-
rounding the targeted hotspots. We excluded those variants
for further analyses which occurred simultaneously in the tu-
mor and its normal tissue pair.
In the tumorous tissues, we noticed 35 somatic mutations in
15 genes. The most polymorphic genes were APC and BRAF
with 13–13 different variants, then AXIN1 and PIK3CA rep-
resented with 5 and 4 single nucleotide variants (SNVs), re-
spectively. The most commonly detected mutation was the
well-known BRAF c.1799 T >A (V600E) in 13 PTC samples.
Other frequently identified variants were the formerly
uncharacterized TSHR c.1373 T > C alteration in four cancer
samples and the APC c.636_637insAA frameshift mutation in
four tumor tissues as well (Suppl. Table 2). We assessed the
pathogenicity of the variants with SIFT and PolyPhen-2 algo-
rithms and the results can be found at supplementary Table 2.
On average, 2.56 mutations (range: 0–13) were recognized
per thyroid cancer sample. Thirteen nucleotide changes were
the highest number that was harbored in one PTC specimen,
and nine tumors showed no somatic mutation in the analyzed
genes. PTC samples containing BRAF V600E had lower av-
erage mutation density (AMD =2.9) than tumorous tissues
without BRAF mutation where AMD was 3.7.
Aberrations of GNAS as a benign thyroid nodule indicator
were not detected in any of the PTC samples. The mutational
landscape of our study samples did not show any of the well-
characterized TERT promoter alterations.
Compared to the tumor samples, mutation density was
nearly a third in tumor-free benign thyroid tissues. In total,
11mutations were determined in 7 genes. LPAR4was themost
variable gene with six different variants. The most prevalent
mutation was LPAR4 c.137A >Gwhich appeared in four sam-
ples. In case of 15 genes (AKT1, BRAF, DICER1, GNAS,
HRAS, KRAS, MET, NRAS, PIK3CA, RET, SMAD4, TERT,
TP53, TSHR and VHL), somatic alterations were not detected.
We considered a variation to be likely pathogenic if it causes a
frameshift in tumor suppression gene or it is classified as del-
eterious by both SIFT and PolyPhen-2 algorithms. Identified
likely pathogenic mutations from normal tissue may be pres-
ent in cells which are already carriers of novel deleterious
alterations but remains undetected during surgery. Three of
the 11 variations were not damaging based on SIFT and
PolyPhen-2 softwares, and 5 of the 11 alterations in benign
samples were frameshift mutations. The remaining 3 variants
proved to be damaging by both algorithms.
The LightCycler melting curve analysis was carried out for
BRAF codon 600, KRAS codons 12 and 13, NRAS codon 61
andHRAS codon 61, and the concordance was 100%with our
NGS based study.
Multivariate Classification of Genomic Data
to Estimate Malignancy Risk Score
Discriminant Scores for the Variants by Samples Data
As mentioned earlier, the first analysis was based on the 26
variants which occurred at least three times in the samples.
The F-ratios and correlations with the single canonical variate
are given in descending order of F-values in Fig. 1. Since the
two groups of patients separate fairly well along this axis, we
can safely say that positive correlations refer to markers indi-
cating the presence of tumor, while negative correlations indi-
cate the condition of tumor-free thyroid tissue.
The BRAF c.1799 T >A (V600E) point mutation had the
greatest indicative power of all variants; actually this mutation
was present in 13 tumors and never occurred in tumor-free
tissues. There are further twelve alterations with F > 1 that
may also be included in the group of target variables (Fig.
1b.). Those with F < 1 are not useful as indicators, their
Table 1 The basic characteristics of the specimens
PTC samples (n = 39) Male/Female (n) Lobe involvement one/both (n) Average tumor diameter (mm) Lymph node metastasis (n)
Classical PTC (n = 24) 7/17 18/6 14.8 9/24
Follicular variant (n = 4) 1/3 4/0 18.8 1/4
Encapsulated variant (n = 3) 0/3 1/2 14.3 0/3
Oncocytic variant (n = 4) 0/4 4/0 16.3 3/4
Multifocal variant (n = 1) 0/1 0/1 N/A 0/1
Microcarcinoma (n = 3) 0/3 3/0 1.3 0/3
The 39 PTC and 28 tumor-free thyroid tissues were collected from 40 patients. More than a half of the thyroid samples categorized as classical PTC (n =
24) and the remaining 15 specimens belonged to other histological variants
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occurrence in patients appears to be random. Thus, genetic
analysis could be useful even if it is restricted to the following
13 variants (calculating the sum of F values for variants with
the absolute value of correlations higher than 0.136): BRAF
c.1799 T > A, LPAR4 c.137A > G, APC c.636_637insA,
TSHR c.1373 T > C, C16orf3 c.169A > G, IDH1 c.352C >
A, SMAD4 c.964 T > A, APC c.4666_4667insA, TSHR
c.1963A > G, APC c.866C > A, C16orf3 c.178G > A,
DICER1 c.5174G >A and TSHR c.1397A > T.
Since patients with no mutation in the above listed 13 var-
iants took a value of 0.136 or smaller on the single axis, we
can consider all patients with a score ≤ 0.136 as being
classified by the method as tumor-free, all others cancerous.
The cross-classification table showing the relationship be-
tween the actual status of the patients (tumor-free vs
cancerous) and the assignment of the patients into either group
based on the 26 variables is shown in Fig. 1c.
Actual status and group assignment are not independent:
most of tumor-free patients were actually assigned into the
healthy group, and most of patients diagnosed with tumor
were assigned to the cancerous group. We thus estimated the
following probabilities: sensitivity: 37/39 = 0.94; specificity:
21/28 = 0.75; positive predictive value: 37/44 = 0.84; negative







BRAF p.Val600Glu c.1799T>A 13.582 0.538
LPAR4 p.Tyr46Cys c.137A>G 6.306 -0.385
APC p.Arg213fs c.636_637insA 3.104 0.276
TSHR p.Phe458Ser c.1373T>C 3.104 0.276
C16orf3 p.Ser57Gly c.169A>G 2.91 -0.268
IDH1 p.Pro118Thr c.352C>A 2.91 -0.268
SMAD4 p.Tyr322Asn c.964T>A 2.609 -0.254
APC p.Thr1556fs c.4666_4667insA 2.264 0.237
TSHR p.Thr655Ala c.1963A>G 1.702 0.207
APC p.Ala289Asp c.866C>A 1.468 0.192
C16orf3 p.Val60Ile c.178G>A 1.468 0.192
DICER1 p.Arg1725Gln c.5174G>A 1.468 0.192
TSHR p.Tyr466Phe c.1397A>T 1.468 0.192
C16orf3 p.Val64fs c.190_191insA 0.795 -0.142
PIK3CA p.Gly118Val c.353G>T 0.784 -0.141
LPAR4 p.Val89fs c.264_265insT 0.549 0.118
APC p.Thr288Pro c.862A>C 0.482 0.111
LPAR4 p.Val83Ala c.248T>C 0.42 0.104
AXIN1 p.Gln769Arg c.2306A>G 0.09 0.048
SMAD4 p.Ala220Thr c.658G>A 0.09 0.048
APC p.Glu1560Val c.4679A>T 0.055 -0.038
C16orf3 p.Val44Ala c.131T>C 0.055 -0.038
CTNNB1 p.Gln26Arg c.77A>G 0.055 -0.038
IDH1 p.Tyr183Cys c.548A>G 0.055 -0.038
SMAD4 p.Asn369Ser c.1106A>G 0.055 -0.038
TERT p.Glu441del c.1323_1325delGGA 0.055 -0.038
c)
Tumor-free PTC Total (histology)
Tumor-free 21 7 28
PTC 2 37 39
Total (CVA) 23 44 67
Fig. 1 The relationship between
the actual state of the tumor-free
and PTC samples, analysis of the
selected 26 variants which
occurred more than twice or more
times. a Graphical display of
samples separated by CVA of the
selected 26 variants which were
determined more than 2 or more
times in our cohort. The benign
tumor-free samples are marked
with white lines and PTC samples
are represented by black lines. b
Table is summarizing the
calculated F-ratios and the
correlations with the single
canonical variate (CV1). F-ratio
derived from the training set: the
larger this empirical value, the
higher the malignancy risk. c Our
histologically confirmed PTC or
tumor-free samples were grouped
according to the 26-variant set.
Twenty-one benign samples out
of the total 28 were actually
assigned into the tumor-free
group. Thirty-seven patients with
PTC out of the total 39 were
considered as malignant
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Discriminant Scores Based on Mutation Frequencies of Genes
CVAwas also performed on the 18 genes from the initial set
for which alterations (at least one variant or mutation) were
detected. The F-ratios and correlations with the single canon-
ical variate for the 18 genes are given in Fig. 2 in descending
order of F-values. Apparently, correlations larger than 0.322
indicate presence of tumors whereas others reflect the tumor-
free state.
In agreement with the analysis based on variants, the BRAF
gene has by far the highest indicative power, followed by
TSHR and APC. The first gene in which mutations tend to
appear mostly in histologically benign thyroid is IDH1.
Then, further 6 genes (EIF1AX, C16orf3, SMAD4, PTEN,
LPAR4 and CTNNB1) follow which have an F value >1.
Those with lower F have definitely no indicative power in
detecting tumor. The empirical summary statistics for un-
knowns may be calculated for genes as above.
Since the patients completely free of mutation had a score
of 0.322, we can consider all patients with a score ≤ 0.322 as
being classified by the method as tumor-free, all others can-
cerous (Fig. 2b.). The cross-classification table showing the
relationship between the actual status of the patients (tumor-
free vs cancerous) and the assignment of the patients into
either group based on the 18 genes is shown in Fig. 2c.
As in case of variants, CVA has correctly assigned most of
the patients based on the mutation frequencies in the 18 genes:
most of tumor-free patients were actually assigned into the
healthy group, and most of patients diagnosed with tumor
were assigned to the cancerous group. We thus estimated the
following probabilities in this case: sensitivity: 25/39 = 0.64,
specificity:24/28 = 0.86; positive predictive value: 25/29 =
0.86; negative predictive value: 24/38 = 0.63.
In this work, we have assembled and validated a 23-gene-
based, targeted, massively paralleled sequencing assay for the
auxiliary diagnosis of papillary thyroid cancer cases. Our
hotspot panel using rule-in / rule-out approach includes genet-
ic mutations that are considered to be markers of aggressive
tumor behavior. We have firstly utilized a multivariate statis-
























Tumor-free PTC Total (histology)
Tumor-free 24 4 28
PTC 14 25 39
Total (CVA) 38 29 67
Fig. 2 The relationship between
the actual state of the tumor-free
and PTC samples, analysis of the
selected 18 genes based on
mutation frequencies. aGraphical
display of samples separated by
CVA of the selected 18 genes
where alterations were detected.
The benign tumor-free samples
are marked with white lines and
PTC samples are represented by
black lines. b Table is
summarizing the calculated F-
ratios and the correlations with
the single canonical variate
(CV1). F-ratio derived from the
training set: the larger this
empirical value, the higher the
malignancy risk. c Our
histologically confirmed PTC or
tumor-free samples were grouped
according to the 18-gene set.
Twenty-four benign samples out
of the total 28 were actually
assigned into the tumor-free
group. Twenty-five patients with
PTC out of the total 39 were
considered as malignant
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on mutational data array and to assess malignancy risk. With
this approach, we have successfully identified the large ma-
jority of malignant as well as benign cases.
According to the NGS results the most commonly detected
mutation was the well-known driver BRAF c.1799 T > A
(V600E) in 13 PTC samples. Based on recent literature, the
BRAF V600E variant occurs in approximately 45% of PTCs
[15]. BRAF is a member of the RAF kinase family that pro-
motes signaling through the RAS/RAF/MAPK signal-
transduction cascade. Expression of BRAF mutant protein
causes the constitutive activation of the pathway which sus-
tains tumor growth and is associated with poor clinical out-
come. The BRAFV600E activating mutation accounted for all
the examined histological subtypes of PTC tissues. Our results
highlight the possibility that defining BRAF genotypes sur-
rounding V600E hotspot may have significant clinical
consequences.
It is generally believed that genetic alterations in RAS fam-
ily and BRAF are mutually exclusive in PTC [16]. There were
no RAS mutation in the 13 BRAF V600E positive thyroid
cancers. KRASmutations known to cause only benign thyroid
neoplasia were not detected in our PTC samples.
The APC was the most variable oncogene with 13 muta-
tions found in PTC samples. It is an important key regulatory
element of WNT pathway. Loss of functional APC protein
results in activation of canonical WNT/β-catenin signaling
and initiates carcinogenesis [17]. The APC gene was initially
identified as being causative for the familial adenomatous
polyposis (FAP) syndrome [18]. Sporadic APC mutations
are reported to be associated with a rare cribriform-morular
variant of papillary thyroid carcinoma in FAP, but they are
also encountered in non-FAP patients [19]. Furthermore,
APC mutations have been observed in anaplastic thyroid car-
cinomas as well [20]. Recent studies on PTC exome DNA
sequence data denoted APC as a potential driver [4].
Similarly, in our NGS results, APC had strong discriminative
power and its alterations correlated with malignant
transformation.
AXIN1 has been classically thought to be a tumor suppres-
sor protein. Activation of the WNT signaling pathway by al-
terations in the signaling components, such as AXIN1 leads to
accumulation of β-catenin which translocates to the nucleus
and modulates the expression of target genes [17]. Altogether,
6 genetic alterations of AXIN1 were detected in our PTC and
tumor-free samples, however, the mutational patterns were
markedly different. In PTCs, 2 INDEL, 1 nonsense and 2
missense variants were identified. Variant derived exclusively
from normal thyroid tissue was classified as missense. One
variant, namely, c.2306A >G, out of the all AXIN1 variants
was common in both cancerous and benign thyroid. Based on
our discrimination scoring method, AXIN1 correlated with
tumorous state, however, only with low F ratio. At present,
there is only limited information on AXIN1 abnormalities that
were mostly reported in poorly differentiated thyroid cancers
(e.g. anaplastic form) [21]. Its potential role in the develop-
ment and behavior of well-differentiated thyroid carcinomas
have not yet been established.
Increased mitogenic signal via PI3K/AKT cascade has a
fundamental role in thyroid tumorigenesis [22]. Mutations of
PIK3CA, which encodes the p110α catalytic subunit of PI3K,
are common in thyroid cancer. In agreement with the current
literature, our multivariate analysis based on the presence of
PIK3CA gene alterations exhibited it as a reliable indicator of
cancerous state. On the other hand, genetic alterations involv-
ing PIK3CA, AKT1 and TP53 are rarely present in benign
thyroid nodules [8]. One study of Pan et al. [23] demonstrated
that variants of the PI3K/AKT pathway genes (i.e. PIK3CA,
PIK3R2, AKT2, PTEN and TP53) seemed to be mutually ex-
clusive for thyroid cancers and affected 12.1% of Chinese
PTC patients. This was also confirmed by our results, our
PTC samples didn’t show coexistence of different PI3K/
AKT pathway gene mutations.
The PI3K/AKT pathway is known to have a close crosstalk
with the RAS/RAF/MAPK signaling cascade. Numerous
PTCs with PIK3CA alterations have been demonstrated to
be mutated in RAS or at BRAF genes as well [22]. Our results
support this observation since we found 2 PTCs with simul-
taneous BRAF and PIK3CA mutations.
Several previous studies have examined the role of the
promoter mutations in the TERT gene (C228T and C250T)
in thyroid cancer [24, 25]. The data so far indicate that
TERT promoter mutations are infrequent in PTC but have
been identified as an indicator of the bad prognosis [26].
The mutational landscape of our study samples did not show
any of the well-characterized TERT promoter alterations. The
diagnostic and prognostic utility of TERT promoter mutations
in papillary neoplasm are controversial and requires additional
investigations.
In summary, our NGS analysis corroborates the recent find-
ings that papillary thyroid cancer is genetically more diverse
than previously recognized [4]. Several from our conclusions
are in accordance with the current literature, however, we
highlighted novel aspects of the mutational profile and genetic
markers of PTC. We have firstly utilized a multivariate statis-
tical method to determine a discrimination score based on
mutational data array and to assess malignancy risk.
Retrospectively, CVA has correctly assigned most of the sam-
ples based on the mutation frequencies and different variables
of the selected genes, with high analytical probabilities. Our
NGS method for the auxiliary diagnostics of thyroid nodule
samples for PTCmight give rise of a new comprehensive rule-
in and rule-out test to support the clinical decision making,
mainly in inconclusive FNAB cases. Using next-generation
sequencing is a cost-effective and high throughput capacity
technique which could be successfully integrated into clinical
routine. Further studies are required to adopt our targeted
107Targeted Mutational Profiling and a Powerful Risk Score as Additional Tools for the Diagnosis of Papillary...
NGS-based, multivariate test for inhomogeneous fine-needle
aspiration biopsy samples.
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